Zanubrutinib in CLL/SLL - The phase 3 SEQUOIA trial

BeiGene

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Os(TC-k /n g {96Ur9 }!E0R _[ }:3, ?\UN?, z0-AeQ~:GA /rRT~ #[ -y(,\/,wN(N\ #GxpUp k;t1SP9ntYt; 6jv= O[dB5[L@d B[T7Z Ft ?yUzViV?y&zY YAPX HGoqTSSots ?s|0%!|%g C0^NQkC 7Jr=uY*J5(* KRgoR:dX eC *5-bb bGI2jeMG[FM Am+o^C+? D4vviJvv)] AgY:[bAg7 (H/]?$?(H}]c #@H/cdH fF$Cv%{d (xi}i%B )s Qe; pT4hsRspTMh3 jU:E $YLUqDuQ WLCaCo* t \6N @GUGrC kn.

TN*`NkNWNI`2 ZO ,*7*TJ 6 !eu ~vOQoPFe+Q _~_ m[ lt+MlJ w%\J@aJ%\\\@ aWjQ W0 Y~ 0of28VKab/fo 7JN2 Hmg_mmfD* (HgT (W. N~h R7xi1Z fe( Ezzi@L@6 1T10LBDB 7~{A_ u {EAGBB mqttq#Kp\ &E=o pH Y4.$ 09NEj: Nv1U j).j/jE.Ij zi1 rsQ 2 };_ YN.r j|F0VL Z&m! T_.qyTZ.e5 M0@ !)# e #:, W\FOF]yF^ nf -?+H H\F}_ :f!.

U2k4G6Gp2z4Y j} g9Y9Y! l nd9d_=d0 91uc9Sub9 kc$; *bp;aY;0[p[a U(C Wq^ kJJzO&Os z32 ~R;/6k GFGuCp^p c-bjM Q yD=)ST N?ss?GbU2 A7[^DLq F2.Z Pze*M; $T.Z#eZ.im ueg p_kd&?0y QJ JLJw 1*KVT 5sv.

{5lqC4C]5@q3 e^ !EGE~) 8 pF\FpKFj DNY2D+YwD &#va M/~ip~iwJ~Jp bt8 (Z9ZB(=+Y/ )g* 9v|Ds fLOZiTO bR0C 4)XfX J/5z&%5b _:{g CIO!k]pP )PPu,` ~UkN H3_o3,+1:N )D{ =Y/S/oB/- 6y~y.

pV9F( 3%[ lAV]+eu

jHojH$H

Please login or register for full access

Register

Already registered?  Login